Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, Tashiro N
Hizen National Hospital, Saga, Japan.
Ther Drug Monit. 2001 Feb;23(1):75-7. doi: 10.1097/00007691-200102000-00014.
A patient had phenytoin intoxication after administration of fluvoxamine, a selective serotonin reuptake inhibitor. The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. During phenytoin and fluvoxamine treatment, ataxia, a typical side effect of phenytoin, was observed. The genotypes of CYP2C9 and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles (CYP2C9*1/1 and 2C191/ *1). The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.
一名患者在服用选择性5-羟色胺再摄取抑制剂氟伏沙明后出现苯妥英中毒。尽管苯妥英和其他药物的每日剂量未变,但在联合使用氟伏沙明时,苯妥英的血清浓度从16.6微克/毫升急剧升至49.1微克/毫升。在苯妥英和氟伏沙明治疗期间,观察到了苯妥英的典型副作用共济失调。负责苯妥英代谢的酶CYP2C9和2C19的基因型为野生型等位基因纯合子(CYP2C9*1/1和2C191/*1)。这种相互作用可能是氟伏沙明对CYP2C9和2C19两者均产生抑制作用的结果。